Eli Lilly and Company and Walmart have joined forces to make it easier for people to buy Zepbound single-dose vials directly through LillyDirect. Starting in mid-November, Zepbound will be available for pickup at Walmart pharmacies across the country. LillyDirect’s self-pay pricing offers at least a 50 percent discount compared to other GLP-1 medicines used for obesity, giving patients a more affordable way to get treatment without needing insurance.

Health Technology Insights: Next Health Brings Proactive Medicine 4.0 Model To Colorado

Zepbound single-dose vials will be available in all approved strength levels, starting at $349 per month for the lowest dose under self-pay. Patients with a valid, on-label prescription can access Zepbound either in person at Walmart pharmacies or through certified delivery partners. This system fits well with existing treatment and surgical routines, helping patients get their medications on time and supporting consistent, reliable treatment results.

Jennifer Mazur, senior vice president and general manager of LillyDirect, said the partnership aims to help reduce the physical, emotional, and financial stress of dealing with chronic conditions like obesity. She explained that combining LillyDirect’s patient-centered platform with Walmart’s wide pharmacy network makes it easier for patients to begin and keep taking their prescribed medications while still accessing genuine Lilly treatments.

Health Technology Insights: Genentech’s Gazyva Shows Positive Phase III Results in Youth

Kevin Host, senior vice president of pharmacy at Walmart, noted that the partnership offers patients convenient options to pick up their medications from trusted pharmacists and pharmacy technicians. Prescriptions for Zepbound can be sent electronically from a healthcare provider to LillyDirect Self Pay Pharmacy Solutions, and patients can choose between free home delivery or picking up their medication at a local Walmart, giving them flexibility based on their needs. The price for Zepbound is $349 per month for the 2.5 mg starting dose and $499 per month for higher doses, with the higher price available through the Zepbound Self Pay Journey Program, which ensures ongoing care under specific terms.

LillyDirect’s self-pay option has seen rapid growth, with about 35 percent of new Zepbound prescriptions in the second quarter of 2025 being filled through the platform. Jennifer Mazur said this growth shows a shift toward more consumer-driven healthcare. She added that by working with Walmart, LillyDirect is improving patient choice and convenience, making more authentic medications accessible, and supporting patients through their entire treatment journey while promoting a more modern, patient-centered approach to care.

Health Technology Insights: Claritev Invests in Klaim to Boost Provider Payments

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com